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Abstract
Background: Prenylated Rab acceptor 1 domain family member 3 (PRAF3) is involved in the regulation of many
cellular processes including apoptosis, migration and invasion. This study was conducted to investigate the effect
of PRAF3 on apoptosis, migration and invasion in human esophageal squamous cell carcinoma (ESCC).
Methods: The expression of PRAF3 mRNA and protein in primary ESCC and the matched normal tissues (57cases)
was determined by quantitative RT-PCR and Western blot. Immunohistochemical analysis of PRAF3 expression was
carried out in paraffin-embedded sections of ESCC and correlated with clinical features. The role of PRAF3 in
apoptosis, migration and invasion was studied in ESCC cell lines of Eca109 and TE-1 through the adenovirus
mediated PRAF3 gene transfer. The effect of PRAF3 on apoptosis was analyzed by annexin V-FITC assay. The
regulation of PRAF3 on migration was determined by transwell and wounding healing assay, while the cellular
invasion was analyzed by matrigel-coated transwell assay.
Results: We found that the expression of PRAF3 was significantly down-regulated in ESCC tissue compared with
the matched normal tissue and was correlated with the clinical features of pathological grade, tumor stage and
lymph node metastasis. Moreover, overexpression of PRAF3 induced cell apoptosis through both caspase-8 and
caspase-9 dependent pathways, and inhibited cell migration and invasion by suppressing the activity of both
MMP-2 and MMP-9 in human ESCC cell lines.
Conclusions: Our data suggest that PRAF3 plays an important role in the regulation of tumor progression and
metastasis and serves as a tumor suppressor in human ESCC. We propose that PRAF3 might be used as a potential
therapeutic agent for human ESCC.
Background
Esophageal squamous cell carcinoma (ESCC) is one of
the most common malignant tumors in China, Japan,
and southeast Africa [1,2]. Although novel surgical
treatment can prolong the survival time of the patients,
t h e5 - y e a rs u r v i v a lr a t eo fE S C Ca f t e rs u r g e r yi sl o w
(ranging from 14%-22%) [3]. The major causes leading
to the poor prognosis of the ESCC patients is tumor
metastasis. Therefore, any insight into the mechanisms
of ESCC cell progression and metastasis may provide
important clues for the development of therapeutics [4].
Prenylated Rab acceptor 1 domain family member 3
(PRAF3, also known as ARL6IP5 and JWA) is a 21.6-kD
microtubule-associated protein containing a prenylated
Rab acceptor (PRA) motif [5,6]. Previous studies
reported that PRAF3 is involved in the regulation of
intracellular protein transport, DNA damage repair, oxi-
dative stress and other functions, where PRAF3 has
been shown to induce cell apoptosis and inhibit cell
migration via different pathways [7-10]. In recent years,
PRAF3 has gained increasing attention in tumor
research. Unlike other members (PRAF1 and PRAF2) of
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and migration and hence may function as oncogenes
[11-13], PRAF3 is considered as a tumor suppressor
since it could induce cell apoptosis and inhibit metasta-
sis in tumors such as breast cancer, cervical cancer, mel-
anoma and osteosarcoma [7,9,10]. However, the
biological role of PRAF3 in ESCC has not been
documented.
Here we set out to evaluate the role of PRAF3 in
human ESCC by clinical investigation and cellular
experiment. Clinical investigation showed that a down-
regulation of PRAF3 expression was closely correlated
with poorly differentiated grading, advanced tumor stage
and lymph node metastasis of ESCC. With ESCC cell
lines, we further demonstrate that overexpression of
PRAF3 by adenovirus-mediated gene transfection could
induce apoptosis and inhibit the migration and invasion.
These results are consistent with the notion that PRAF3
is a suppressor in ESCC.
Methods
ESCC specimens
A total of fifty-seven primary ESCC patients that under-
went esophagectomy were enrolled in this study. Tumor
specimens and paired normal esophageal tissue speci-
mens taken from a site distant from the cancerous
lesion were obtained from the consenting patients, as
approved by the Medical Ethics Committee of Yixing
People’s Hospital. None of the patients received radio-
therapy or chemotherapy before surgery. Clinical and
pathological data including age, gender, pathological
grading, tumor location, tumor stage and lymph node
metastasis were acquired from the medical records.
Cell culture
Human ESCC cell lines Eca109 and TE-1 were pur-
chased from the Shanghai Institute of Biochemistry and
Cell Biology (Shanghai, China). Cells were maintained in
RPMI1640 (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 100 U/ml penicillin and 100
μg/ml streptomycin, within a humidified atmosphere
containing 5% CO2 at 37°C.
Immunohistochemistry
We used primary ESCC tissues near the margin of the
tumor and match normal tissues to asses PRAF3 expres-
sion. Sections (5 μm) of the specimens were incubated
with goat anti-human PRAF3 antibody (Santa Cruz)
overnight at 4°C, followed by incubation with horserad-
ish peroxidase-conjugated donkey anti-goat antibody
(Santa Cruz) for 1 hr at 37°C. Immunodetection was
performed with the EnVision™ Kit (Dako), using diami-
nobenzidine as the chromogen. All slides were evaluated
independently by two pathologists (ZJG. and JZ.)
without prior knowledge of the clinical information of
t h ep a t i e n t s .T h ee x p r e s s i o no fP R A F 3w a sc o n s i d e r e d
positive if staining intensity was moderate or strong and
the percentage of positively stained cancer cells were >
10%.
Construction of recombinant adenovirus Ad.PRAF3 and
cell infection
Recombinant adenovirus expressing human PRAF3 was
constructed using the AdEasy system (Stategene).
Human PRAF3 gene was amplified and ligated into
pShuttleCMV plasmid. Ad.PRAF3 and Ad.Null were
propagated in HEK293 cells and purified using BD
Adeno-X™ virus purification kit (BD Biosciences). The
activities of adenovirus were determined by plaque assay
using BD Adeno-X™ rapid titer kit (BD Biosciences)
according to the manufacturer’s instruction. Cells from
ESCC cell lines were infected with Ad.PRAF3 (or Ad.
Null) at a MOI of 100 for 12 hr at 37°C, where the per-
centage of infected cells were 84.7% and 79.3% as
detected by Ad.GFP in Eca109 and TE-1, respectively.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from 100 mg tissues or 1 ×
10
5 cells using the RNeasy RNA Mini Kit (Qiagen). First
strand cDNA was synthesized using POWERSCRIPT
reverse transcriptase (Clontech). The following gene-
specific primer pairs were used for quantitative PCR:
PRAF3:F o r w a r d ,5 ’- TCATGTTGGCGAGC-
TATTTCC -3’;
Reverse, 5’- GGTTCCGAAGTCTCAACGATG-3’.
GAPDH:F o r w a r d ,5 ’- GCTGAGTATGTCGTG-
GAGTC -3’;
Reverse, 5’- AGTTGGTGGTGCAGGATGC -3’.
PCR was performed using a Fast Start Master SYBR
Green Kit (Roche) on a LightCycler (Roche). The
expression level of target gene mRNA was analyzed
using RealQuant software (Roche) and normalized to
that of GAPDH mRNA.
Cell lysis and western blot
For preparation of membrane and cytoplasmic protein
samples, the tissue or cell samples were harvested in
hypotonic lysis buffer (10 mM Tris-HCl, pH 7.5, 10 mM
NaCl, 0.2 mM EDTA, 1 mM DTT) supplemented with
inhibitors (25 mM b glycerol-phosphate, 25 mM NaF, 1
mM Na3VO4, 1 mM PMSF, 1 mM benzamidine,). Cell
l y s a t e sw e r ep r e p a r e db yD o u n c eh o m o g e n i s a t i o na n d
centrifuged at 500 g for 5 min to eliminate nuclei and
debris. The supernatant was subjected to ultracentrifu-
gation at 20,000 g for 60 min using the TLA-100.2 fixed
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man). The supernatant (cytoplasm) was adjusted to 100
mM NaCl and 0.5% Nonidet P-40. The membrane pellet
was resolubilised in NETN buffer (50 mM Tris-HCl, pH
7.5, 100 mM NaCl, 200 mM EDTA, 0.5% Nonidet P-40,
1 mM DTT, supplemented with inhibitors).
Equal amounts of protein (50 μg) were separated by
10% SDS PAGE and then transferred to nitrocellulose
membranes (NY) by electroblotting. The membranes
were blocked with 5% BSA in TBST (10 mM Tris-HCl,
pH 8.0, 150 mM NaCl, and 0.05% Tween 20) for 1 hr,
and then incubated with mouse anti-human specific
antibodies overnight at 4°C before subsequent incuba-
tion with horseradish peroxidase-conjugated goat anti-
mouse antibody (BD Biosciences) for 1 hr at 37°C. Pro-
tein was visualized using enhanced chemiluminescence
reagent (Santa Cruz). The expression level of target pro-
tein was analyzed using LabWork 4.0 program (UVP)
and normalized to that of b-actin protein.
Zymography analysis
The activity of MMP-2 and MMP-9 was detected by
zymography analysis. The supernatants of ESCC cells
(1.0 × 10
6) were mixed with sample buffer (10 mM
Tris-HCl, pH 7.5, 10 mM NaCl, 0.2 mM EDTA) without
reducing agent or heating. The sample was loaded into a
gelatin (1 mg/ml) containing SDS-polyacrylamide gel
and separated by PAGE. Then, the gel was washed with
2.5% TritonX-100 to remove SDS, rinsed with 50 mM
Tris-HCl, pH 7.5, and subsequently incubated overnight
at room temperature with the developing buffer (50
mM Tris-HCl, pH 7.5, 5 mM CaCl2,1 mM ZnCl2, 0.02%
thimerosal, 1% Triton X-100). The zymographic activ-
ities were revealed by LabWork 4.0 program after stain-
ing with 1% Coomassie Blue.
Apoptosis assay
Cell apoptosis was analyzed by annexin V-FITC assay.
Briefly, cells were treated with RNase A (50 mg/ml) for
30 min at 37°C and then stained with annexin V-FITC
and propidium iodide using the ANNEXIN V-FITC Kit
(Beckman) according to the manufacturer’s protocol and
subjected to flow cytometric analysis. Viable cells were
unstained by annexin V or propidium iodide, early
apoptotic cells were stained by annexin V but not propi-
dium iodide, and late apoptotic cells were stained by
annexin V and propidium iodide.
Caspases activity assay
ApoAlert caspase fluorescent and colorimetric assays
(BD Biosciences) were used to measure the activity of
caspase-8 and caspase-9. Cells (1.0 × 10
6) were collected
and lysed in ice-cold buffer by homogenating. Caspase
activity in the supernatant was determined by cleavage
of the specific chromophore-conjugated substrates. The
substrate peptides of caspase-8 (IETD) and caspase-9
(LEHD) were conjugated to p-nitroaniline (p-NA), and
7-amino-4-methyl coumarin (AMC), respectively. Cas-
pase-8 activity was determined by absorbance of p-NA
at 405 nm in a microplate reader. The release of AMC
for caspase-9 was measured by quantifying fluorescent
intensity in a fluorescence spectrophotometer.
Wound healing assay
ESCC cells were seeded on 6-well plates at a density of
5×1 0
5 cells/well. After the cells reached sub-conflu-
ence, the mono-layer cells were wounded by scraping
off the cells and then grown in medium for 48 h. The
migrated distance of cells was monitored and imaged
under a microscope. The distances of cell migration
were calculated by subtracting the distance between the
lesion edges at 48 hr from the distance measured at 0 h.
The relative migrating distance of cells is measured by
the distance of cell migration/the distance measured at
0h .
Transwell assay
Cell migration and invasion were determined using a
transwell (Costar) with a pore size of 0.8 μm. 1 × 10
5
cells were seeded in serum-free medium in the upper
chamber (normal chamber for migration assay and
matrigel-coated chamber for invasion assay), while med-
ium containing 10% FBS in the lower chamber. After
incubating for 8 hr at 37°C, cells in the upper chamber
were carefully removed with a cotton swab and the cells
that had traversed to reverse face of the membrane were
fixed in methanol, stained with Giemsa, and counted.
Statistical Analyses
Statistical significance was tested using SPSS15.0 soft-
ware. For comparisons of clinical features except for
pathological grading between PRAF3 positive and nega-
tive groups, chi-square test was performed. The correla-
tion between PRAF3 expression and pathological grade
was analyzed by Cochran-Mantel-Haenszel Statistics.
Other data are presented as mean ± SEM, using student
t tests for 2-group comparisons. A P value less than
0.05 is considered statistically significant.
Results
PRAF3 expression is down-regulated in ESCC specimens
and is correlated with pathological grade, tumor stage
and lymph node metastasis
In the present study, we evaluated the expression of
PRAF3 in ESCC and the matched normal esophageal
tissues by immunohistochemical analysis. It was found
that PRAF3 was weakly expressed in ESCC tissues,
whereas it was moderately expressed in normal
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and western blot, we revealed that the expression level
of PRAF3 mRNA and protein was significantly down-
regulated in tumor tissue compared with the matched
normal tissue (Figure 1B and 1C). These data suggest
that down-regulation of PRAF3 might be associated
with esophageal tumorigenesis.
We further analyzed the relationship between PRAF3
expression and the clinical features including age, gen-
der, pathological grade, tumor location, tumor stage and
lymph node metastasis in ESCC. It was found that the
expression of PRAF3 was significantly correlated with
pathological grade (P = 0.0498), tumor stage (P =
0.0208) and lymph node metastasis (P = 0.0343); while
there was no significant correlation between PRAF3
expression and other factors (Table 1). These results
suggest that the PRAF3 might be involved in the pro-
gression and metastasis of ESCC.
Overexpression of PRAF3 induces apoptosis of ESCC cells
PRAF3 was reported to be required for the arsenic tri-
oxide and C/EBP-a induced apoptosis [8,9], however
the effect of PRAF3 alone on tumor cell apoptosis has
not been mentioned before. Here we employed Eca109
a n dT E - 1( B o t hd e r i v e df r o mw ell-differentiated ESCCs
[14,15]) as model system to evaluate the effect of PRAF3
on the cell apoptosis through adenovirus mediated
PRAF3 gene transfer. It was found that the expression
of PRAF3 mRNA and protein was significantly increased
in the ESCC cells treated with Ad.PRAF3 as compared
to the cells treated with Ad.Null at 72 hr post-infection
(Figure 2A and 2B). Using annexin V-FITC assay, we
found that in cell lines (Eca109 and TE-1), the percen-
tage of annexin V-FITC
+/PI
- and annexin V-FITC
+/PI
+
in Ad.PRAF3-infected cells were both significantly
higher than those in Ad.Null-infected cells (Figure 2C).
T h e s ed a t ai n d i c a t et h a to v e r e x p r e s s i o no fP R A F 3p r o -
motes apoptosis of ESCC cells.
PRAF3 induces ESCC cell apoptosis through both caspase-
8 and caspase-9 dependent pathways
Caspase-8 and caspase-9 are identified as the principal
upstream caspase effectors in death receptor pathway
and death receptor-independent pathway of cell apopto-
sis, respectively [16,17]. To investigate the mechanism of
PRAF3 in the regulation of ESCC cell apoptosis, we
evaluated the activity of caspase-8 and caspase-9 in
Eca109 and TE-1 cells infected with Ad.PRAF3 (or Ad.
Null). As shown in Figure 3A and 3B, the activity of
both caspase-8 and caspase-9 was significantly increased
in cells treated with Ad.PRAF3 compared with those
cells treated with Ad.Null. Furthermore, western blot
analysis showed that overexpression of PRAF3 triggered
both caspase-8 and caspase-9 cleavage (Figure 3C).
These results indicate that PRAF3 could induce ESCC
cell apoptosis through both the caspase-8 and caspase-9
dependent pathways.
Overexpression of PRAF3 inhibits the migration and
invasion of ESCC cells
To investigate the role of PRAF3 in ESCC metastasis, we
detected the migrant and invasive capacity of ESCC cells
(Eca109 and TE-1) infected with Ad.PRAF3 or Ad.Null.
Through transwell and wound healing assay, we found
that the percentage of cells travelled through the micro-
pore membrane was significantly decreased, and the rela-
tive migrating distance of cells was significantly shorter in
Ad.PRAF3-infected cells as compared to the Ad.Null-
Figure 1 PRAF3 expression is down-regulated in ESCC
specimens as compared to matched normal tissues. (A)
Representative images of immunohistochemical staining for PRAF3
in normal esophageal epithelium and esophageal squamous cell
carcinoma. Expression level of PRAF3 protein was moderate in
normal esophageal epithelium, whereas it was weak in ESCC. Bars =
100 μm. (B, C) The expression of PRAF3 mRNA and protein in the
ESCC specimens and the matched normal tissues was detected by
qRT-PCR and western blot and normalized to that of GAPDH and b-
actin, respectively. Results showed that the expression level of
PRAF3 mRNA (B) and protein (C) was significantly down-regulated
in tumor tissue compared with the matched normal tissue. Data
represent mean ± SEM from 57 paired specimens; *, P < 0.05, **, P
< 0.01 by paired t test.
Shi et al. BMC Cancer 2012, 12:97
http://www.biomedcentral.com/1471-2407/12/97
Page 4 of 12infected cells (Figure 4A-D). In addition, by matrigel-
coated transwell assay, we revealed that the percentages of
Ad.PRAF3-infected Eca109 and TE-1 cells that invaded
through the matrigel were significantly lower than those of
Ad.Null-infected cells (Figure 4E and 4F). These results
indicate that overexpression of PRAF3 inhibits the migra-
tion and invasion of ESCC cells.
PRAF3 suppresses the activity of MMP-2 by integrin aVb3
signaling in ESCC cells
Previous studies reported that MMP-2 was closely
related to the metastasis of ESCC [18]. Therefore, we
detected the effect of PRAF3 on the activity and expres-
sion of MMP-2 in ECA109 and TE-1 ESCC cells. As
shown in Figure 5A and 5B, the activity of MMP-2 in
the ESCC cells infected with Ad.PRAF3 was significantly
decreased in comparison with those cells infected with
Ad.Null. However, the expression level of MMP-2 pro-
tein was comparable between the two groups (Figure
5B). These results indicate that PRAF3 suppresses the
activity but not the expression of MMP-2.
Since it was reported that PRAF3 inhibited melanoma
metastasis by integrin aVb3 signaling [10] and integrin
aVb3 could promote tumor metastasis by activating
MMP-2 [19], we further analyzed the expression of integ-
rin aV and b3 subunits in ESCC cells infected with Ad.
PRAF3 (or Ad.Null) by western blot. It was found that
the expression level of integrin aV and b3 in Ad.PRAF3-
infected cells was significantly lower than that in Ad.
Null-infected cells (Figure 5C and 5D). These data sug-
gest that PRAF3 might suppress the activity of MMP-2
by down-regulating integrin aVb3 signaling in ESCC cells.
PRAF3 suppresses the expression of MMP-9 by affecting
the membranous location of CCR5 in ESCC cells
MMP-9 was another matrix metalloproteinase which
was closely related to the metastasis of ESCC [18]. Here,
we detected the effect of PRAF3 on the activity and
expression of MMP-9 in ESCC cells. It was found that
both the activity and expression of MMP-9 in Ad.
PRAF3-infected cells was significantly lower than those
in Ad.Null-infected cells (Figure 6A and 6B). These
results suggest that PRAF3 could suppress the activity of
MMP-9 by inhibiting its expression.
In light of previous findings that the expression of
MMP-9 was up-regulated by CCL5/CCR5 axis [20] and
PRAF3 protein contains a CCR5 binding motif [21], we
hypothesized that PRAF3 might inhibit the expression
of MMP-9 through its regulation of CCR5. To test the
hypothesis, we further studied the effect of PRAF3 on
the expression of CCR5 in ESCC cells. In the present
study, we found that the expression of CCR5 at the
plasma membrane was significantly lower in Ad.PRAF3-
infected cells as compared to Ad.Null-infected cells
Table 1 Relationship between the expression of PRAF3 and clinical features
clinical features esophageal squamous cell carcinoma
PRAF3-positive n (%) PRAF3-negative n (%) test P
Total 24 33
Age (year)
< 60 13/24 (54.2) 19/33 (57.6) 0.0656 0.7979
≥ 60 11/24 (45.8) 14/33 (42.4)
Gender
Male 17/24 (70.8) 25/33 (75.8) 0.1738 0.6768
Female 7/24 (29.2) 8/33 (24.2)
Pathological grading
Well 11/24 (45.9) 6/33 (18.2) 5.9991 0.0498
Moderately 8/24 (33.3) 12/33 (36.4)
Poorly 5/24 (20.8) 15/33 (45.4)
Tumor location
Upper 1/3 middle 1/3 15/24 (62.5) 23/33 (70.0) 0.3239 0.5693
Lower 1/3 9/24(37.5) 10/33 (30.0)
Tumor stage
T1/T2 13/24 (54.2) 8/33 (24.2) 5.347 0.0208
T3/T4 11/24 (45.8) 25/33 (75.8)
Lymph node metastasis
Negative 14/24 (58.3) 10/33 (30.3) 4.4785 0.0343
Positive 10/24 (41.7) 23/33 (69.7)
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cell lysate was comparable between the 2 groups (Figure
6D). These data suggest that PRAF3 could suppress the
expression of MMP-9 by affecting the membranous
location of CCR5 in ESCC cells.
Discussion
Members of the Prenylated Rab acceptor domain family
(PRAF) are essential for the regulation of many cellular
processes [22,23]. Here we have demonstrated that
PRAF3 could induce apoptosis and inhibit migration
Figure 2 Overexpression of PRAF3 induces apoptosis of ESCC cells. Eca109 and TE-1 cells were infected with Ad.PRAF3 (or Ad.Null) at a
MOI of 100. The expression of PRAF3 and its effect on cell apoptosis were detected at 72 hr post-infection. (A, B) The expression level of PRAF3
mRNA and protein was detected by qRT-PCR and western blot and normalized to that of GAPDH and b-actin, respectively. Histogram showed
the expression level of PRAF3 mRNA (A) and protein (B) in Ad.PRAF3 -infected and Ad.Null -infected ESCC cells. (C) Cells were stained with
annexin V-FITC and propidium iodide (PI). Flow cytometric contour plots showed the percentage of stained cells. Histogram showed the
percentage of Annexin V
+/PI
- and Annexin V
+/PI
+ cells of Ad.PRAF3-infected and Ad.Null-infected ESCC cells. Data represent mean ± SEM from 4
independent experiments; **, P < 0.01 by t test.
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6 Eca109 and TE-1 cells were
infected with Ad.PRAF3 (or Ad.Null) at a MOI of 100. The activity and expression of caspase-8 and caspase-9 were detected at 72 hr post-
infection. (A, B) The activity of caspase-8 and caspase-9 were detected by ApoAlert caspase colorimetric and fluorescent assays, respectively. The
activity of the Ad.Null-infected cells at 0 hr was defined as 1. Histogram showed the activity of caspase-8 (A) and caspase-9 (B) in Ad.PRAF3-
infected and Ad.Null-infected ESCC cells. (C, D) The expression of caspase-8 and caspase-9 were detected by western blot and normalized to
that of b-actin. Photographs showed the western blot products and histograms showed the expression of caspase-8 (C) and caspase-9 (D) in
Ad.PRAF3-infected and Ad.Null-infected ESCC cells. Data represent mean ± SEM from 4 independent experiments; *, P < 0.05, **, P < 0.01 by t
test.
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tumor suppressor in ESCC.
Although the role of PRAF3 has been studied in sev-
eral other tumors using tumor cell lines [7,9,10,24],
there is a lack of investigation into the relationship
between PRAF3 expression and the clinical features of
ESCCs. In the present study, we found that the expres-
sion level of PRAF3 mRNA and protein in ESCC tis-
sues was significantly lower than that in the matched
normal tissues. In addition, we found that down-regu-
lation of PRAF3 expression was significantly correlated
with poorly differentiated grading, advanced tumor
Figure 4 Overexpression of PRAF3 inhibits the migration and invasion of ESCC cells. Eca109 and TE-1 cells were infected with Ad.PRAF3
(or Ad.Null) at a MOI of 100. Migration and invasion of cells treated with Ad.PRAF3 (or Ad.Null) were analyzed at 72 hr post-infection. (A) Wound
healing assay. Photographs represented the cells migrated into the wounded area and histogram showed the relative migration distance of cells.
(B) Transwell assay. Photographs represented the cells travelled through the micropore membrane and histogram showed the percentage of
migrant cells. (C) Matrigel-coated transwell assay. Photographs represented the cells invaded through the matrigel and histogram showed the
percentage of invasive cells. Bars = 100 μm. Data represent mean ± SEM from 4 independent experiments; **, P < 0.01 by t test.
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Page 8 of 12Figure 5 Overexpression of PRAF3 suppresses the activity of MMP-2 and the expression of integrin aV and b3. 1.0 × 10
6 Eca109 and TE-
1 cells were infected with Ad.PRAF3 (or Ad.Null) at a MOI of 100. The activity of MMP-2 in supernatants, and the expression of MMP-2, integrin
aV and integrin b3 were detected at 72 hr post-infection. (A) The activity of MMP-2 was detected by zymography assay and the activity of the
Ad.Null-infected cells was defined as 1. Photographs represented the gelatin zymography and histograms showed the activity of MMP-2 in Ad.
PRAF3-infected and Ad.Null-infected ESCC cells. (B-D) The expression of MMP-2, integrin aV and integrin b3 were detected by western blot and
normalized to that of b-actin. Photographs showed the western blot products and histograms showed the expression level of MMP-2 (B),
integrin aV (C) and integrin b3 (D) protein in Ad.PRAF3-infected and Ad.Null-infected ESCC cells. Bars = 100 μm. Data represent mean ± SEM
from 4 independent experiments; *, P < 0.05, **, P < 0.01 by t test.
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1.0 × 10
6 Eca109 and TE-1 cells were infected with Ad.PRAF3 (or Ad.Null) at a MOI of 100. The activity of MMP-9 in supernatants, and the
expression of MMP-9 and CCR5 were detected at 72 hr post-infection. (A) The activity of MMP-9 was detected by zymography assay and the
activity of the Ad.Null-infected cells was defined as 1. Photographs represented the gelatin zymography and histograms showed the activity of
MMP-9 in Ad.PRAF3-infected and Ad.Null-infected ESCC cells. (B) The expression of MMP-9 was detected by western blot and normalized to that
of b-actin. Photographs showed the western blot products and histograms showed the expression level of MMP-9 protein in Ad.PRAF3-infected
and Ad.Null-infected ESCC cells. (C, D) The expression of CCR5 in total cell lysate and at plasma membrane were detected by western blot and
normalized to that of b-actin. Photographs showed the western blot products and histograms showed the expression of CCR5 in total cell lysate
(C) and at plasma membrane (D) in Ad.PRAF3-infected and Ad.Null-infected ESCC cells. Data represent mean ± SEM from 4 independent
experiments; *, P < 0.05, **, P < 0.01 by t test.
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r e s u l t sw o u l di m p l yt h a tP R A F 3m a yp l a ya ni m p o r t a n t
role in regulating the progression and metastasis of
ESCCs, although further in vivo studies are needed to
substantiate this conclusion. We noticed that the
expression of PRAF3 in normal squamous tissue is not
homogeneous and appeared as a decreasing gradient
from the differentiating squamous compared to the
transit amplifying and stem cell compartment. How-
ever, there is a lack of information regarding the role
of PRAF3 in the regulation of differentiation of normal
squamous cells. In this sense, it would be interesting
to see whether down-regulation of PRAF3 expression
would result in retarded differentiation of normal
squamous cells.
Apoptosis is a form of cellular suicide that closely
related to the progression and metastasis of tumor cell
[25]. Previous studies showed that PRAF3 serves as an
important regulator in cell apoptosis [8,9,24]. For exam-
ple, Zhou et al. demonstrated that the expression of
PRAF3 is up-regulated and required for the arsenic tri-
oxide induced tumor cell apoptosis in Hela and MCF-7
[9]. Wang et al showed that PRAF3 is a key mediator in
C/EBP-a induced cell apoptosis of HEK293 and
NIH3T3 [8]. However, whether changes in PRAF3
expression alone affect tumor cell apoptosis has not
been reported. In the present study, we have examined
the effect of PRAF3 on the cell apoptosis through ade-
novirus mediated PRAF3 gene transfer. We demonstrate
that overexpression of PRAF3 induces cell apoptosis in
human ESCC.
Cell apoptosis mainly involves two signaling pathways:
the death receptor pathway and the death receptor-inde-
pendent (or mitochondrial) pathway [16]. Caspase-8 and
caspase-9 have been identified as the key signal mole-
cules of the two pathways respectively [26,27]. In the
present study, we showed that overexpression of PRAF3
could significantly increase the activity of both caspase-8
and caspase-9 in ESCC cells, suggesting that PRAF3
could induce ESCC cell apoptosis through both caspase-
8 and caspase-9 dependent pathways. Notably, we found
that the overexpression of PRAF3 induced greater
changes in caspase-9 than caspase-8 expression, suggest-
ing that PRAF3 may induce cell apoptosis mainly
through the death receptor-independent pathway in
human ESCC.
Tumor metastasis is the leading cause of low survival
rate of ESCC patients. Previous studies showed that
PRAF3 acts as a down-regulatory factor for cell migra-
tion and invasion in melanoma, osteosarcoma, cervical
cancer and breast cancer [7,10]. In the present study, we
investigated the role of PRAF3 in ESCC metastasis by
clinical investigation and cellular experiment. As men-
tioned above, our clinical investigation suggests that the
expression of PRAF3 in ESCC is negatively related to
the tumor metastasis. Moreover, with ESCC cell lines
infected with Ad.PRAF3, we further demonstrate that
overexpression of PRAF3 significantly inhibits the
migration and invasion of ESCC cells. Our results indi-
cate that down regulation of PRAF3 may contribute to
the metastasis of ESCC.
It is well known that matrix metalloproteinases
(MMPs), a family of zinc- dependent endopeptidases,
are involved in tumor metastasis in many aspects such
as tumor-induced angiogenesis, tumor invasion, and
establishment of metastatic foci at the secondary site,
etc [28-30]. Among the many MMPs, MMP-2 and
MMP-9 are reported to be closely related to the tumor
metastasis in ESCC [18]. However, whether PRAF3 reg-
ulates the activity of MMP-2 and MMP-9 in ESCC has
not been documented. In the present study, we found
that overexpression of PRAF3 significantly suppressed
the activity of both MMP-2 and MMP-9, suggesting that
PRAF3 could inhibit ESCC metastasis partially through
the repression of MMP-2 and MMP-9 dependent
pathway.
Previous study showed that PRAF3 could suppress the
activity of MMP-2 by modulating the integrin avb3 sig-
naling in melanoma [10]. Here we show that overex-
pression of PRAF3 did not alter the expression of
MMP-2 but significantly repressed the expression of
integrin av and b3, suggesting that PRAF3 may inhibit
the activity of MMP-2 probably by the inhibition of
integrin avb3 signaling in ESCC cells.
On the other hand, we found that the expression of
MMP-9 was significantly lower in Ad.PRAF3 treated
cells than the controls. Since it was reported that the
expression of MMP-9 was regulated by CCL5/CCR5
axis [20] and PRAF3 contains a CCR5 binding motif
[21], we further studied the affection of PRAF3 on the
CCR5. Our data show that overexpression of PRAF3 did
not alter the level of CCR5 in the total cell lysate but
significantly decreased the level of CCR5 at the plasma
membrane. Considering that PRAF3 is a transmembrane
protein located at the endoplasmic reticulum [21], we
propose that PRAF3 might suppress the traffic of CCR5
from endoplasmic reticulum to plasma membrane, and
thereby inhibits the expression and in turn the activity
of MMP-9.
Conclusions
We found that PRAF3 expression in ESCC tissues was
significantly lower than that in matched normal tissues
and was correlated with the clinical features of patholo-
gical grade, tumor stage and lymph node metastasis.
Moreover, overexpression of PRAF3 induces apoptosis
and inhibits migration and invasion in ESCC cells.
Based on these findings, we propose that PRAF3 might
Shi et al. BMC Cancer 2012, 12:97
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Page 11 of 12be a lead molecule for the development of novel treat-
ment of ESCC.
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